+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 1 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating the effects of several drugsvismodegib, FAK inhibitor GSK2256098, capivasertib, and abemaciclibin treating patients with progressive meningiomas, which are brain tumors that are growing, spreading, or worsening. This phase II trial specifically targets meningiomas with certain genetic mutations affecting pathways such as SMO, PTCH1, NF2, AKT1, PIK3CA, PTEN, and CDK. The study aims to measure how well these targeted drugs can slow tumor progression and improve response rates over six months. Participants are assigned to one of four treatment groups based on their tumors mutation profile. Those with SMO or PTCH1 mutations receive vismodegib once daily, NF2 mutations receive FAK inhibitor GSK2256098 twice daily, AKT1PIK3CAPTEN mutations receive capivasertib twice daily on days 1-4 weekly, and those with CDK pathway alterations receive abemaciclib every 12 hours. Treatment cycles last 28 days and continue unless the disease progresses or side effects become unacceptable. After completing treatment, participants are followed every six months for up to five years. During the study, participants undergo regular evaluations including imaging to measure tumor size and response, safety monitoring for adverse events, and assessments of progression-free and overall survival. Laboratory tests, electrocardiograms, and other clinical assessments support safety and eligibility monitoring. The main outcomes focus on progression-free survival at six months and confirmed tumor response, while secondary outcomes include overall survival and side effect rates. Participants remain under close observation throughout their treatment and follow-up periods.

Age: 18Years +All GendersPhase 2
791 locations